1026TiP A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumorsMehmet Altan, Assuntina G. Sacco, Minal Barve et al.|Annals of Oncology|2021Cited by 0